Calquence is a prescription drug approved by the Food and Drug Administration (FDA) to treat mantle cell lymphoma. Calquence is indicated in cases where at least one previous therapy has been tried. Calquence is also referred to by its drug name, Acalabrutinib.
Calquence is used as targeted therapy for lymphoma. Calquence is a member of a class of drugs called kinase inhibitors. Calquence is believed to work by inhibiting replication and triggering cell death in lymphoma cells.
How do I take it?
Prescribing information states that Calquence is taken orally every 12 hours.
Calquence comes in the form of a capsule.
Side effectsread more
The FDA-approved label for Calquence lists common side effects including fatigue, headache, muscle pain, bruising, diarrhea, and low blood cell counts.
Rare but serious side effects listed for Calquence include increased risk for infections, abnormal bleeding, and later development of other cancers such as skin cancer and carcinomas.
For more details about this treatment, visit:
Calquence – AstraZeneca
Targeted Therapy Drugs for Non-Hodgkin Lymphoma – American Cancer Society